---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-074975"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:56:49.128674+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q2 net income $545K vs loss last year; license revenue up to $1.0M

## Summary
- Net income from continuing operations $545K ($0.05/share) vs net loss of -$1.05M (-$0.09) in Q2 2024.
- License revenue $1.0M, up $0.7M from $234K, driven by changes in Mayne License Agreement product sales.
- Total operating expenses fell 45.5% to $1.647M, primarily due to no impairment in current quarter.
- Cash and equivalents $6.1M as of June 30, 2025; company continues strategic alternatives review.
- No timetable set for strategic transaction outcome; no assurance of any deal.

## SEC filing metadata
- accession: 0001213900-25-074975
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000121390025074975/0001213900-25-074975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000121390025074975/ea0252348-8k_therap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-074975
- JSON: https://secwatch.observer/filing/0001213900-25-074975.json
- Plain text: https://secwatch.observer/filing/0001213900-25-074975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.